In a transgenic NSE/APPsw AD mouse model carrying the mutated human APP gene, the degree of tau phosphorylation and content of Aβ1-42 in the brain of mice were significantly reduced within 5 weeks after the injection of NSCs. The gene discussed is MAPT; the disease is Alzheimer disease.